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Abstract
Venous thromboembolism (VTE) carries a high morbidity and mortality and leads to 
a substantial economic burden. From the traditional perspectives, liver cirrhosis tends 
to bleeding but not VTE. However, modern concepts suggest that liver cirrhosis is 
also at a risk of VTE. The pooled incidence and prevalence of VTE in liver cirrhosis are 
1% (95% confidence interval: 0.7–1.3%) and 1% (95% confidence interval: 0.7–1.2%), 
respectively. Evidence indicates that a higher international normalized ratio and a 
lower albumin should be associated with a higher probability of VTE in liver cir‐
rhosis. Additionally, the presence of VTE significantly worsens the outcomes of liver 
cirrhosis.
Keywords: venous thromboembolism, liver cirrhosis, risk factor, prognosis, 
epidemiology
1. Introduction: venous thromboembolism
Venous thromboembolism (VTE) consists of deep vein thrombosis (DVT) and pulmonary 
embolism (PE). VTE is a major public health condition.
First, VTE represents a substantial economic burden in this world. A systematic review of 
10 cost‐of‐illness studies explored the costs in the different regions [1]. The initial VTE costs 
3000–9500$ in the United States. The additional inpatient costs are significantly increased 
with the duration of VTE. In the United States, the VTE over 3, 6, and 12 months costs 5000$, 
10,000$, and 33,000$, respectively; by comparison, in the EU, the VTE over 3 and 12 months 
costs 1800$ and $32,000$, respectively. The additional costs of VTE‐related complications are 
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also expensive. The post‐thrombotic syndrome costs 426–11,700$, and the heparin‐induced 
thrombocytopenia costs 3118–41,133$.
Second, VTE carries a relatively high incidence. In the United States, the annual incidence of 
VTE is 1/1000 and is gradually increased with the age [2]. A 25‐year population‐based study, 
which was conducted in Olmsted County, Minnesota, United States, found that the annual 
incidence of VTE was 1.17/1000 and that the annual incidences of DVT and PE were 0.48/1000 
and 0.69/1000, respectively [3]. A community‐based study, in which 342,000 inhabitants were 
enrolled between April 1, 1998, and March 31, 1999, in Western France, demonstrated that the 
annual incidence of VTE was 1.83/1000 (95% confidence interval: 1.69–1.98) and that the annual 
incidences of DVT and PE were 1.24/1000 (95% confidence interval: 1.12–1.36) and 0.60/1000 
(95% confidence interval: 0.52–0.69), respectively [4]. Recently, a new community‐based study, 
in which 367,911 inhabitants were enrolled between March 1, 2013, and February 28, 2014, in 
Western France, demonstrated that the annual incidence of VTE was significantly decreased 
to 1.57/1000 (95% confidence interval: 1.44–1.69) [5]. A prospective community‐based study, 
in which 151,923 permanent residents of northeastern metropolitan Perth in Western Australia 
were followed from October 1, 2003, to October 31, 2004, found that the annual incidence 
of VTE was 0.83/1000 (95% confidence interval: 0.69–0.97) and that the annual incidences of 
DVT and PE were 0.52 (95% confidence interval: 0.41–0.63) and 0.31 (95% confidence interval: 
0.22–0.40), respectively [6]. Indeed, necropsy examinations demonstrated a higher incidence 
of VTE. Based on a review of necropsy reports from a Swedish Malmo general hospital, 34.7% 
(347/994) of necropsy cases had VTE, and 9.4% (93/994) of them had fatal PE [7].
Third, VTE produces a high mortality and is a major cause of death in the general population. 
A population‐based cohort study of 2218 patients with DVT or PE from Olmsted County, 
Minnesota, demonstrated that the 7‐day, 30‐day, and 1‐year survival rates were 96.2, 94.5, 
and 85.4% in patients with DVT alone and 59.1, 55.6, and 47.7% in patients with PE with or 
without DVT [8]. A retrospective review of necropsy data from inpatients at King's College 
Hospital between January 1991 and December 2000 demonstrated that 5.2% (265/6833) of 
death cases were attributed to fatal PE [9]. The VTE Impact Assessment Group in Europe 
(VITAE) estimated that the total number of symptomatic VTE events per annum within the 
six EU countries, including France, Germany, Italy, Spain, Sweden, and the United Kingdom, 
were 465,715 (404,664–538,189) DVT cases, 295,982 (242,450–360,363) PE cases, and 370,012 
(300,193–483,108) VTE‐related deaths [10].
2. Risk factors for the development of VTE
Virchow's triad, which includes vessel injury, blood flow stasis, and hypercoagulopathy, 
is a classical explanation for the development of VTE [11]. According to the 7th American 
College of Chest Physicians Conference on Antithrombotic and Thrombolytic Therapy, the 
major risk factors for VTE included surgery, trauma (major or lower extremity), immobility, 
paresis, malignancy, cancer therapy (hormonal, chemotherapy, or radiotherapy),  previous 
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VTE, increasing age, pregnancy and the postpartum period, estrogen‐containing oral contra‐
ception or hormone replacement therapy, selective estrogen receptor modulators, acute med‐
ical illness, heart or respiratory failure, inflammatory bowel disease, nephrotic  syndrome, 
myeloproliferative disorders, paroxysmal nocturnal hemoglobinuria, obesity, smoking, 
varicose veins, central venous catheterization, and inherited or acquired thrombophilia [12]. 
Currently, accumulated evidence has identified more and more risk factors for the devel‐
opment of VTE. A meta‐analysis of 14 studies demonstrated a dose‐response relationship 
between duration of travel and development of VTE [13]. Hippisley‐Cox et al. developed and 
validated the QThrombosis web calculator (www.qthrombosis.org) for predicting the risk of 
VTE between 1 and 5 years [14]. In the calculator, the information should be provided regard‐
ing age, sex, ethnicity, smoking status, varicose vein surgery, chronic kidney disease (stage 4 
or 5), cancer, heart failure, chronic obstructive airways disease, Crohn's or ulcerative colitis, 
previous admission in last 6 months, antipsychotics, and body mass index. For women, some 
additional information regarding hormone replacement therapy, an oral contraceptive, and 
tamoxifen is needed. Rogers et al. also conducted a case‐crossover study to evaluate the trig‐
gers of hospitalization for VTE [15]. A total of 399 subjects with VTE hospitalizations were 
enrolled from the Health and Retirement Study in the United States. The investigators found 
that infection was the most frequent trigger of VTE (52.4%) and the use of erythropoiesis stim‐
ulating agents was the most strong trigger of VTE (adjusted incidence rate ratio = 9.33, 95% 
confidence interval: 1.19–73.42). More recently, Tsai et al. [16] also assessed the hospital‐level 
determinants of VTE diagnosis. An interesting finding was that patients treated in urban hos‐
pitals had a higher risk of VTE diagnosis than those treated in rural hospitals. Except for the 
above‐mentioned findings in the general population, lots of studies focused on the prediction 
of VTE in patients with cancer, patients undergoing surgery, and other specific population, 
which were beyond the scope of the present work.
3. Liver cirrhosis
According to the Global Burden of Disease Study 2010, liver cirrhosis is the 11th leading 
cause of death and accounts for 50,000 deaths in the United States, 2010 [17]. It is also the 
8th leading cause of years of life lost from premature death. According to the Global Burden 
of Disease Study 2013, liver cirrhosis is the 13th leading cause of global years of life lost 
[18]. The major complications of liver cirrhosis should be esophageal variceal bleeding 
and  ascites [19–21]. Liver cirrhosis is divided into four major stages according to the two 
complications. They include stage 1 (neither varices nor ascites), stage 2 (varices without 
ascites), stage 3 (ascites), and stage 4 (variceal bleeding) [22]. Considering the potential risk 
of lethal variceal bleeding, a patient with liver cirrhosis is considered to have a bleeding 
diathesis and is often contraindicated for antithrombotic drugs [23]. At present, emerging 
evidence suggests that a cirrhotic patient is also at a risk of thrombosis due to the loss of 
anticoagulant proteins [23]. A nationwide Danish case‐control study of 99,444 patients with 
VTE and 496,872 population controls found a significantly higher risk of VTE in patients 
with liver cirrhosis (all VTE: risk ratio = 1.74, 95% confidence interval: 1.54–1.95; DVT: risk 
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ratio = 2.02, 95% confidence interval: 1.78–2.31; PE: risk ratio = 1.41, 95% confidence interval: 
1.20–1.65) [24]. Additionally, a nationwide US population‐based study of 408,253 admis‐
sions with compensated cirrhosis, 241,626 admissions with decompensated cirrhosis, and 
575,057 admissions without liver diseases demonstrated a significantly higher risk of VTE in 
cirrhotic patients younger than 45 years (compensated cirrhosis: adjusted odds ratio = 1.23, 
95% confidence interval: 1.04–1.46; decompensated cirrhosis: adjusted odds ratio = 1.39, 95% 
confidence interval: 1.15–1.69) [25].
4. Epidemiology of VTE in liver cirrhosis
The prevalence and incidence of VTE in liver cirrhosis are greatly heterogeneous among 
studies. Thus, our team systematically reviewed and synthesized the data regarding the epi‐
demiology of VTE in liver cirrhosis [26]. Among the 20 included studies, the pooled inci‐
dence and prevalence of VTE in liver cirrhosis were 1% (95% confidence interval: 0.7–1.3%) 
and 1% (95% confidence interval: 0.7–1.2%), respectively; the pooled incidence and preva‐
lence of DVT in liver cirrhosis were 0.6% (95% confidence interval: 0.4–0.8%) and 0.7% (95% 
confidence interval: 0.6–0.9%), respectively; the pooled incidence and prevalence of PE in 
liver cirrhosis were 0.28% (95% confidence interval: 0.13–0.49%) and 0.36% (95% confidence 
interval: 0.13–0.7%), respectively. Such epidemiological data should be important for physi‐
cians and patients to recognize the potential risk of VTE.
5. Risk factors for VTE in liver cirrhosis
Due to the relative rarity of VTE in liver cirrhosis, it is necessary to obtain the knowledge 
regarding risk factors for VTE and to further screen high‐risk patients who will receive 
medical prophylaxis for VTE. Except for traditional risk factors in the general population 
(i.e., older age, comorbidity, surgery), which were reported in the second paragraph of 
this article, two risk factors related to liver diseases have been more widely recognized, 
such as international normalized ratio (INR) and albumin. First, cirrhotic patients often 
have an elevated INR, which reflects an auto‐anticoagulation status. Thus, it appeared to 
be reasonable that the risk of VTE would be lower if INR was higher. However, this was 
not the case. Northup et al. for the first time found that the risk of VTE was not associated 
with INR [27]. Dabbagh et al. also confirmed that an elevated INR did not protect against 
the development of VTE during hospitalization [28]. Smith et al. showed that the risk of 
in‐hospital VTE was similar between patients with INR <2.0 and INR ≥2.0 [29]. Indeed, our 
team observed a positive relationship between INR and risk of VTE [30]. This phenomenon 
should be explained by the fact that INR is a component of Child‐Pugh score and reflects 
the severity of liver dysfunction, rather than the absolute hemostasis disturbance. Second, 
several studies coherently found a lower albumin in cirrhotic patients with VTE than those 
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without [27, 31–33]. But a statistical significance was achieved in only two of them [27, 33]. 
Taken together, a prediction algorithm of VTE in liver cirrhosis should be warranted.
6. Prognosis of liver cirrhosis and VTE
6.1. Effect of VTE on the survival in cirrhotic patients
By analyzing the data from the Nationwide Inpatient Sample (1998–2006), Wu et al. found 
that the in‐hospital mortality of compensated cirrhosis was 16.8 and 7.6% in patients with and 
without VTE, respectively (odds ratio = 2.16, 95% confidence interval: 1.96–2.38); the in‐hos‐
pital mortality of decompensated cirrhosis was 18.6 and 11.1% in patients with and without 
VTE, respectively (odds ratio = 1.66, 95% confidence interval: 1.47–1.87) [25]. More recently, 
a single‐center retrospective study of 2006 admissions with cirrhosis by our team also demon‐
strated an approximately 10‐fold higher in‐hospital mortality in patients with VTE than those 
without VTE (33.3 vs. 3.4%, P < 0.001) [30].
6.2. Effect of liver cirrhosis on the survival in VTE patients
A nationwide Danish cohort study of 4392 VTE patients, which included 745 and 
3647patients with and without cirrhosis, respectively, explored the effect of cirrhosis on 
the 30‐day death [34]. According to the sites of VTE, the 30‐day mortality was 7% (95% 
 confidence interval: 5–10%) and 3% (95% confidence interval: 2–3%) in DVT patients with 
cirrhosis and without liver cirrhosis, respectively; the 30‐day mortality was 35% (95% con‐
fidence interval: 29–42%) and 16% (95% confidence interval: 14–19%) in PE patients with 
cirrhosis and without liver cirrhosis, respectively.
6.3. Effect of liver cirrhosis on the development of cancer in VTE patients
A population‐based Danish cohort study of 2755 VTE patients with liver diseases, which 
included 1867 VTE patients with non‐cirrhotic liver diseases and 888 VTE patients with liver 
cirrhosis, explored the effect of cirrhosis of the development of cancer [35]. VTE patients 
with liver cirrhosis had a significantly higher 1‐year risk of cancer than VTE patients with 
non‐cirrhotic liver diseases (4.3 vs. 2.7%).
7. Conclusions
Physicians should recognize that cirrhotic patients are at a risk of VTE. Once VTE is diag‐
nosed, the outcomes of cirrhotic patients would be worse. INR and albumin should be poten‐
tial risk factors of VTE in cirrhosis. However, until now, no prediction model for VTE in such 
patients was well established.
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